A Model-based Framework to Address Dose Modifications
This work tackles a central challenge in oncology drug development: predicting benefit-risk for dosing regimens that have not yet been studied. Semi-mechanistic modeling can be used for this purpose, but model validation is complicated by the presence of safety-driven dose modifications—such as delays and reductions—commonly observed in real-world settings.